Medcare reports 5 Moviva weight-loss cases in Dubai, testing demand for cash-pay obesity care

Medcare Royal Speciality Hospital says it has introduced Moviva gastric mucosal ablation in Dubai, a no-incision endoscopic weight-loss procedure that gives UAE clinics a new cash-pay obesity service and insurers a new evidence question.

The highest-stakes readers are clinic CEOs, CFOs and medical directors. The story matters because obesity treatment in the UAE is moving into a middle category between dietetics, GLP-1 drugs and bariatric surgery. Dubai providers fall under the Dubai Health Authority (DHA). Abu Dhabi and Al Ain providers need to read the same commercial opportunity through Department of Health Abu Dhabi (DOH) licensing. Northern Emirates operators sit under the Ministry of Health and Prevention (MOHAP).

What Medcare says it has launched

Biz Today reported on 24 August 2026 that Medcare Royal Speciality Hospital has introduced Gastric Mucosal Ablation, known commercially as Moviva, as a UAE-first advanced minimally invasive weight-loss procedure. A full version of the same release reported that five patients had undergone the procedure at Medcare and named losses of 18 kg, 36 kg, 32 kg and 26 kg among four patients.

The procedure is performed through the mouth with an endoscope. It targets the gastric fundus, where ghrelin, a hunger-related hormone, is produced. Erbe, the German medical-device company behind Moviva, describes the procedure as gastric mucosal ablation using injection and argon plasma coagulation. The device maker says the approach may be used alone or with endoscopic sleeve gastroplasty.

"Moviva addresses the biological drivers of weight gain rather than simply restricting food intake." Dr. Mohamed Abdelhafez, Consultant Gastroenterology, Medcare Royal Speciality Hospital

The clinical evidence is still early. A listed study of endoscopic gastric mucosal ablation, NCT05486338, enrolled adults aged 22 to 60 with BMI criteria that included BMI 30 to 40 with an obesity-related comorbidity, or BMI above 40 to 45. The study followed patients for up to 12 months. Mayo Clinic reported in March 2026 that 10 GFMA-only patients had 7.7% body-weight loss at six months, while a GFMA plus endoscopic sleeve gastroplasty approach reached 23.5% total body-weight loss in early work.

What clinics and insurers should check

The first commercial question is pricing. Medcare has not published a direct UAE tariff in the source article. A public medical-tourism listing for Moviva at Medcare cites $8,168.82 for Moviva alone and $16,337.65 with suturing. At the UAE dollar peg, that is about AED 30,000 and AED 60,000. CFOs should treat those as benchmark quotes, then request direct package pricing that separates endoscopy suite time, anaesthesia, physician fees, dietetics follow-up and complication cover.

Insurers are likely to ask whether the treatment is medically necessary, investigational, cosmetic or part of a covered obesity pathway. Daman, Thiqa and Sukoon should be named in contracting discussions only when a provider has written policy language or pre-authorisation guidance in hand. Clinics should avoid marketing reimbursement certainty until payer coding, exclusions and pre-approval rules are documented.

• Eligibility: use BMI, comorbidity status, prior dietetics attempts and endoscopy fitness as documented criteria.
• Commercial model: assume cash-pay until a payer confirms pre-authorisation terms in writing.
• Operations: build a pathway with gastroenterology, anaesthesia, dietetics and follow-up visits at one, three, six and 12 months.
• Risk file: keep device training records, informed consent, adverse-event reporting and outcome tracking ready for regulator inspection.

Why this matters in the UAE

MOHAP said in January 2026 that 22.4% of UAE adults are living with obesity, alongside 25.9% with high blood pressure and 12.5% with elevated blood glucose. That creates a large addressable pool, but a large pool does not make every new procedure a reimbursable service.

For Dubai operators, the near-term opportunity is a structured obesity programme rather than a single procedure line. DHA-licensed facilities need to decide whether Moviva belongs inside gastroenterology, bariatric endoscopy or multidisciplinary weight management. In Abu Dhabi, DOH-licensed hospitals should run the same assessment against endoscopy service requirements and clinical governance. In Sharjah, Ajman, Umm Al Quwain, Ras Al Khaimah and Fujairah, MOHAP-regulated providers should check whether their current facility licence and staff privileges cover this procedure before advertising it.

Patients will ask three practical questions: am I eligible, how much will I pay, and what happens if weight returns. Clinics that can answer with audited outcomes at six and 12 months will have an advantage over providers selling the novelty of the device. For licensed nutrition and dietetics support around obesity care, readers should use the UAE Open Healthcare Directory to find regulated providers before referring or contracting.